from ABIONYX (EPA:ABNX)
Inside Information / Other news releases
Press Release
ABIONYX Pharma announces its financial calendar for the year 2026
Toulouse, FRANCE, Fullerton, CA, USA, January 23, 2026, 7:00 p.m. CET - ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today announces its financial calendar for 2026.
| Events | Dates* |
|---|---|
| Cash position and activity update for Q4 2025 | Thursday, February 26, 2026 |
| 2025 Full-Year Results | Thursday, March 12, 2026 |
| Cash position and activity update for Q1 2026 | Thursday, May 28, 2026 |
| Cash position and activity update for Q2 2026 | Thursday, August 27, 2026 |
| 2026 Half-Year Results | Thursday, September 24, 2026 |
| Cash position and activity update for Q3 2026 | Thursday, November 26, 2026 |
* indicative dates subject to change
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through breakthrough biotherapies that address life-threatening conditions with no effective treatments. Leveraging its proprietary apoA-I–based technology platform, ABIONYX Pharma develops innovative biologics and HDL-derived vectors that target the immune and inflammatory dysregulation underlying sepsis and other severe diseases. With a strong scientific foundation and a growing network of global clinical partners, ABIONYX Pharma aims to redefine the standard of care in sepsis and to bring critical care solutions to patients worldwide.
Contacts :
ABIONYX Pharma
infos@abionyx.com